Michael Higgins
Stock Analyst at Ladenburg Thalmann
(0.65)
# 3,010
Out of 4,415 analysts
21
Total ratings
25%
Success rate
-14.07%
Average return
Main Sectors:
12 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FBRX Forte Biosciences | Upgrades: Buy | $2.75 | $0.69 | +298.44% | 2 | Apr 8, 2024 | |
| MRNS Marinus Pharmaceuticals | Maintains: Buy | $17 → $13 | $1.45 | +796.55% | 1 | Aug 11, 2023 | |
| OVID Ovid Therapeutics | Reiterates: Buy | $7 | $3.07 | +128.01% | 1 | May 2, 2023 | |
| SCYX SCYNEXIS | Reiterates: Buy | $15 | $1.78 | +742.70% | 1 | Apr 3, 2023 | |
| ARTL Artelo Biosciences | Reiterates: Buy | $60 | $1.38 | +4,247.83% | 2 | Apr 3, 2023 | |
| VRDN Viridian Therapeutics | Reiterates: Buy | $40 | $14.58 | +174.35% | 3 | Mar 9, 2023 | |
| RYTM Rhythm Pharmaceuticals | Reiterates: Buy | $35 | $40.98 | -14.59% | 3 | Mar 2, 2023 | |
| PTN Palatin Technologies | Maintains: Buy | $2 → $50 | $2.05 | +2,339.02% | 1 | Sep 9, 2022 | |
| PHGE BiomX | Maintains: Buy | $13 → $8 | $0.41 | +1,860.78% | 2 | May 12, 2022 | |
| NVAX Novavax | Downgrades: Sell | n/a | $4.71 | - | 2 | Aug 5, 2020 | |
| VIRT Virtu Financial | Upgrades: Buy | n/a | $22.07 | - | 2 | Jan 4, 2019 | |
| SVRA Savara | Reinstates: Buy | n/a | $4.68 | - | 1 | Sep 27, 2017 |
Forte Biosciences
Apr 8, 2024
Upgrades: Buy
Price Target: $2.75
Current: $0.69
Upside: +298.44%
Marinus Pharmaceuticals
Aug 11, 2023
Maintains: Buy
Price Target: $17 → $13
Current: $1.45
Upside: +796.55%
Ovid Therapeutics
May 2, 2023
Reiterates: Buy
Price Target: $7
Current: $3.07
Upside: +128.01%
SCYNEXIS
Apr 3, 2023
Reiterates: Buy
Price Target: $15
Current: $1.78
Upside: +742.70%
Artelo Biosciences
Apr 3, 2023
Reiterates: Buy
Price Target: $60
Current: $1.38
Upside: +4,247.83%
Viridian Therapeutics
Mar 9, 2023
Reiterates: Buy
Price Target: $40
Current: $14.58
Upside: +174.35%
Rhythm Pharmaceuticals
Mar 2, 2023
Reiterates: Buy
Price Target: $35
Current: $40.98
Upside: -14.59%
Palatin Technologies
Sep 9, 2022
Maintains: Buy
Price Target: $2 → $50
Current: $2.05
Upside: +2,339.02%
BiomX
May 12, 2022
Maintains: Buy
Price Target: $13 → $8
Current: $0.41
Upside: +1,860.78%
Novavax
Aug 5, 2020
Downgrades: Sell
Price Target: n/a
Current: $4.71
Upside: -
Virtu Financial
Jan 4, 2019
Upgrades: Buy
Price Target: n/a
Current: $22.07
Upside: -
Savara
Sep 27, 2017
Reinstates: Buy
Price Target: n/a
Current: $4.68
Upside: -